Lymphoma

2022 - 9 - 17

Post cover
Image courtesy of "The Cancer Letter"

Dwight Tosh, the 17th patient at St. Jude, on surviving lymphoma in ... (The Cancer Letter)

The interviews are conducted by Deborah Doroshow, assistant professor of medicine, hematology, and medical oncology at the Tisch Cancer Institute, Icahn School ...

“I started having pulmonary heart issues, a disease, when I was in my late forties, and had to have a bypass when I was 48 years of age,” he said. “I made a promise that I was going to return to school, and I was going to prove to these concerned parents that didn’t think that I should be around their kids, that I was going to prove that just because you’ve been a patient at St. “I had lost the arches of both my feet,” he said. “At least I’m still here,” he said. “I developed diabetes, and it’s just, I’ve had to have a hip replacement, and my joints and everything. “There were not that many of us there in that wing of that old hospital,” he said. They were trying everything, but then with a high dosage of radiation and chemo…my body was just almost getting to the point that, like I said, I just didn’t want to do anything, just trying to survive.” “I never got so sick of pecans in all my life, but I was eating those things just nonstop. “It was just devastating,” he said. The day after doctors told Tosh’s family to prepare for the worst, he was transported by ambulance through the doors of St. “And still, the doctors couldn’t figure out or diagnose what the problem was.” Dwight Tosh had grown so weak that he was unable to walk.

Post cover
Image courtesy of "Targeted Oncology"

The State of the Targeted Therapy Landscape for Mantle Cell ... (Targeted Oncology)

In an interview with Targeted Oncology™, Cyrus M. Khan, MD, discussed new strategies for the treatment of mantle cell lymphoma and needs for the future.

From the get-go, I think they need to have the mantle cell patients seen by an experienced center to see whether the patient would qualify for a more aggressive therapy upfront in a clinical trial, and whether they need an autologous transplant. There are a lot of unanswered questions, and a lot of research is going into that too. I think more vigilance is required to treat patients with mantle cell lymphoma. I think we still use aggressive chemotherapy than we take the patients to an autologous transplant for consolidation in the hopes that we would induce a deep remission for a long time. We really were running up choices, but now that's really expanded the portfolio of treatments that we have available in the relapsed/refractory setting. I think that might also add into the whole paradigm of treatments in the future. All 3 are approved in relapsed/refractory mantle cell lymphoma. For those patients, once it becomes relapsed/refractory, it becomes very difficult to treat them. And now the second has been CAR T-cell therapy in the relapsed setting. New therapies are needed in the case of relapse on a BTK inhibitors, and for frontline MCL, and elderly patients. “I think more vigilance is required to treat patients with mantle cell lymphoma. The FDA-approved BTK inhibitors for relapsed/refractory MCL include ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa).

Explore the last week